ArticleScientific reports2025
Detection, localization, and staging of breast cancer lymph node metastasis in digital pathology whole slide images using selective neighborhood attention-based deep learning.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Deep learning in breast cancer histopathology: predicting and detecting axillary lymph node metastasis.Virchows Archiv : an international journal of pathology · 2026Review
- MRNet: A Multi-Resolution Dual-Task Framework for Micrometastases Detection in Breast Cancer Sentinel Lymph Nodes.Journal of imaging informatics in medicine · 2026Article
- Review
- Pixel-level annotations of context region for trustworthy diagnosis of Breast Lymph Node Metastasis from Histopathological WSI.Data in brief · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Accurate detection, localization, and staging of breast cancer lymph node metastases are critical for guiding treatment decisions and predicting patient outcomes. This study presents a selective neighborhood attention-based deep learning framework that combines nuclei-level features with high-level tissue embeddings to detect, annotate and stage breast cancer metastases in whole-slide images (WSIs) of lymph node biopsy specimens precisely. The proposed framework leverages a dual-path feature extractor, incorporating both nuclei segmentation/classification outputs and transformer-based tissue features, alongside a dynamic attention mechanism that selects and emphasizes neighboring patches based on similarity to the target patch. Experimental results on the CAMELYON16 test set demonstrate high performance in patch-level tumor detection, with sensitivity of 96.2 ± 1.5%, precision of 95.3 ± 2.4%, and an F1-score of 95.7 ± 3.1%. The model achieves accurate tumor boundary delineation, evidenced by a Dice score of 90.5 ± 2.0% and a Jaccard index of 82.6 ± 0.8%, along with a lesion-level free-response receiver operating characteristic (FROC) score of 84.6 ± 2.8%. Additionally, the slide-level classification achieves an area under the receiver operating characteristic (ROC) curve (AUC) of 0.96 ± 0.01, highlighting the system's strong diagnostic capability. Out-of-distribution evaluation on the CAMELYON17 dataset confirms the framework's generalizability, yielding an F1-score of 87.0 ± 1.8% at the patch level and an AUC of 0.88 ± 0.03 at the slide level. Furthermore, the proposed model achieves a kappa score of 0.94 ± 0.02 for automated pN-staging at the patient level, indicating near-expert concordance in detecting and classifying the extent of nodal metastasis. Ablation analyses underscore the importance of incorporating nuclei-based features and selective neighborhood attention, with noticeable performance degradation observed when either element is removed. By integrating cellular-level insights with tissue-level contextual information, the proposed framework replicates key aspects of human pathological assessment effectively and shows promise as a decision-support tool in the era of digital pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.